This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Philip Morris (PM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of 4.41% and 2.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: PPG, PG, Philip Morris, Northrop and Danaher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PPG, PG, Philip Morris, Northrop and Danaher
Why Earnings Season Could Be Great for Philip Morris (PM)
by Zacks Equity Research
Philip Morris (PM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
All You Should Know Before Philip Morris' (PM) Q3 Earnings
by Zacks Equity Research
Philip Morris' (PM) third-quarter 2020 results are likely to reflect soft duty-free sales due to the pandemic-led travel restrictions. However, strength in reduced-risk products should aid.
Buy 5 Corporate Giants Ahead of Earnings Results Next Week
by Nalak Das
Five corporate behemoths with a favorable Zacks Rank are poised to beat earnings estimates next week. Investment in these stocks will be fruitful at this stage.
Philip Morris (PM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Philip Morris (PM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Philip Morris (PM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Philip Morris (PM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Lamb Weston (LW) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Lamb Weston's (LW) first-quarter fiscal 2021 performance is likely to reflect adverse impacts of low traffic at restaurants amid the pandemic. Also, increased COVID-19 related costs are a concern.
All You Should Know Before Helen of Troy's (HELE) Q2 Earnings
by Zacks Equity Research
Helen of Troy's (HELE) second-quarter fiscal 2021 results are likely to reflect strength in Leadership brands and online sales.
Oral Tobacco Unit Supports Altria Amid Poor Cigarette Sales
by Zacks Equity Research
Altria (MO) is gaining from rising popularity of low risk tobacco alternatives. However the company's smokeable unit is bearing the brunt of soft cigarette sales.
PepsiCo (PEP) to Report Q3 Earnings: Will It Beat Estimates?
by Zacks Equity Research
PepsiCo's (PEP) Q3 results are likely to reflect gains from increased at-home consumption trends and growth in e-commerce, with strong demand for snacks, energy drinks and ready-to-drink coffee.
Here's All You Should Note Before Conagra's (CAG) Q1 Earnings
by Zacks Equity Research
Conagra Brands' (CAG) first-quarter fiscal 2021 results are likely to reflect strength in the retail business, thanks to solid demand stemming from the pandemic-led higher at-home consumption.
All You Need to Note Before McCormick's (MKC) Q3 Earnings
by Zacks Equity Research
McCormick's (MKC) third-quarter fiscal 2020 results are likely to reflect strength in the Consumer Business unit, though the Flavor Solutions unit has been seeing soft pandemic-led demand.
The Zacks Analyst Blog Highlights: AT&T, Philip Morris, Square, Zoom and Vale
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AT&T, Philip Morris, Square, Zoom and Vale
Here's How United Natural (UNFI) Looks Ahead of Q4 Earnings
by Zacks Equity Research
Increased demand owing to pantry loading of essential items amid the coronavirus outbreak is likely to get reflected in United Natural's (UNFI) fourth-quarter fiscal 2020 performance.
Top Analyst Reports for AT&T, Philip Morris & Square
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Philip Morris International (PM) and Square (SQ).
Here's How General Mills (GIS) Looks Ahead of Q1 Earnings
by Zacks Equity Research
Increased demand owing to higher at-home consumption amid the coronavirus outbreak is likely to get reflected in General Mills' (GIS) first-quarter fiscal 2021 performance.
RRPs a Respite for Philip Morris Amid Low Cigarette Sales
by Zacks Equity Research
Philip Morris (PM) is gaining from growing popularity of IQOS. However, low cigarette sales is a dampener.
4 Tobacco Stocks to Watch Amid Rising Popularity of RRPs
by Zacks Equity Research
Zacks Tobacco industry players like PM, MO, VGR and TPB are poised to benefit from rising popularity of low risk tobacco alternatives such as e-cigarettes and vaping products. However, low cigarette sales volumes are likely to remain a worry.
4 Tobacco Stocks to Watch Amid Rising Popularity of RRPs
by Zacks Equity Research
Zacks Tobacco industry players like PM, MO, VGR and TPB are poised to benefit from rising popularity of low risk tobacco alternatives such as e-cigarettes and vaping products. However, low cigarette sales volumes are likely to remain a worry.
Philip Morris (PM) Hikes Dividend: What Else Should You Know?
by Zacks Equity Research
Philip Morris (PM) rewards shareholders by raising quarterly dividend. Also, the company's expansion of RRP's is yielding.
Things to Know Before Brown-Forman (BF.B) Reports Q1 Earnings
by Zacks Equity Research
Brown-Forman's (BF.B) first-quarter fiscal 2021 results are expected to gain from increased at-home consumption occasions and e-premise growth, offset by soft on-premise and Travel Retail channels.
Factors to Watch Before Campbell Soup's (CPB) Q4 Earnings
by Zacks Equity Research
Campbell Soup's (CPB) fourth-quarter fiscal 2020 results are likely to have gained from rising demand from coronavirus-induced elevated at-home consumption.
Top Stock Reports for Verizon, Novartis & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), Novartis (NVS) and Abbott Laboratories (ABT).
Altria Gains From Oral Products Amid Lower Cigarette Sales
by Zacks Equity Research
Despite dismal cigarette sales, pricing power and growth in oral tobacco are offering Altria (MO) some respite.